This report is designed for companies and decision-makers seeking actionable insights on market size, growth, trends, and competitive strategies to drive expansion and success in the Congestive Heart Failure (CHF) industry.
How has the congestive heart failure (chf) market size changed in recent years, and what is the outlook ahead?
The congestive heart failure (CHF) market size has grown strongly in recent years. It will grow from $15.94 billion in 2024 to $17.10 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to high prevalence of aging population, increasing cardiovascular diseases, rise in awareness of heart health, increasing healthcare expenditure, growth demand for remote patient monitoring.
The congestive heart failure (CHF) market size is expected to see strong growth in the next few years. It will grow to $22.31 billion in 2029 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to rising adoption of digital health solutions, increasing prevalence of hypertension, rising obesity rates, improving patient outcomes, increased focus on personalized medicine. Major trends in the forecast period include advancements in diagnostic technologies, advancements in treatment options, technological advancements in imaging, innovations in therapeutic approaches, developments in wearable health devices.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20730&type=smp
What are the top economic and technological drivers pushing congestive heart failure (chf) market growth?
The increase in cardiovascular patients is expected to propel the growth of the congestive heart failure (CHF) market going forward. Cardiovascular refers to the heart and blood vessels, focusing on their role in circulating blood and maintaining the body’s overall health. The rise in cardiovascular patients is due to sedentary lifestyles, unhealthy diets, ageing populations, and urbanization, leading to a higher need for advanced healthcare and treatment solutions. Congestive heart failure (CHF) is helpful for cardiovascular patients by providing targeted solutions that improve heart efficiency, reduce symptoms, and prevent complications, ultimately enhancing patient care and overall well-being. For instance, in January 2023, according to the American College of Cardiology, a US-based nonprofit medical society, cardiovascular disease cases rose to 19.8 million in 2022. Additionally, Eastern Europe has the highest mortality rate at 553 deaths per 100,000. Therefore, the increase in cardiovascular patients is driving growth in the congestive heart failure (CHF) market.
How is the congestive heart failure (chf) market segmented by product, application, and end-user?
The congestive heart failure (CHF) market covered in this report is segmented –
1) By Type: Systolic Heart Failure, Diastolic Failure, Left-Sided Heart Failure, Right-Sided Heart Failure
2) By Treatment: Medication, Surgery
3) By Diagnosis: Electrocardiogram, Echocardiogram, Magnetic Resonance Imaging (MRI), Stress Test, Blood Tests, Cardiac Catheterization, Other Diagnosis
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
5) By End-User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Homecare Settings
Subsegments:
1) By Systolic Heart Failure: Reduced Ejection Fraction (HFrEF), Mild-to-moderate Reduced Ejection Fraction
2) By Diastolic Heart Failure: Preserved Ejection Fraction (HFpEF), Borderline Ejection Fraction (HFpEF)
3) By Left-Sided Heart Failure: Acute Left-Sided Heart Failure, Chronic Left-Sided Heart Failure
4) By Right-Sided Heart Failure: Acute Right-Sided Heart Failure, Chronic Right-Sided Heart Failure
View The Full Market Report:
https://www.thebusinessresearchcompany.com/report/congestive-heart-failure-chf-global-market-report
What evolving trends are creating new opportunities in the congestive heart failure (chf) market?
Major companies operating in the congestive heart failure (CHF) market are focusing on advanced innovations, such as single intracoronary infusion therapies to offer effective treatment options that improve heart function and enhance the quality of life for CHF patients. Single intracoronary infusion delivers medication directly into the coronary artery, targeting the heart to provide precise treatment for conditions like congestive heart failure (CHF). For instance, in January 2024, Bayer AG, a Germany-based pharmaceutics company, and Asklepios Biopharmaceutical, Inc., a US-based biotechnology company, initiated the GenePHIT Phase II trial for AB-1002, an investigational gene therapy for congestive heart failure (CHF). This innovation utilizes a gene therapy approach to target non-ischemic cardiomyopathy, offering a potential breakthrough in the treatment of CHF through advanced genetic solutions. The trial is adaptive, double-blind, placebo-controlled, and will enroll between 90 and 150 participants who have been medically stable for at least four weeks and have a left ventricular ejection fraction between 15% and 35%.
Which leading companies are dominating the congestive heart failure (chf) market landscape?
Major companies operating in the congestive heart failure (CHF) market are Pfizer Inc., Johnson & Johnson Inc., Boehringer Ingelheim International GmbH, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, Abbott Laboratories, Novartis AG., Medtronic Plc, Eli Lilly and Company, Canon Medical Systems Corporation, Novo Nordisk A/S, Jarvik Heart Inc., Boston Scientific Corporation, Applied Molecular Genetics Inc., Biotronik SE & Co. KG, Exelixis Pharmaceuticals Inc., Otsuka Pharmaceutical Co. Ltd., LivaNova
Which geographic areas are expected to offer the highest growth opportunities in thecongestive heart failure (chf) market?
North America was the largest region in the congestive heart failure (CHF) market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the congestive heart failure (CHF) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Congestive Heart Failure (CHF) Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20730
Need Customized Data On Congestive Heart Failure (CHF) Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/customise?id=20730&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
